Related Experiment Video
Updated: May 12, 2026
Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses
Published on: November 16, 2016
Interferon-γ-induced necrosis: an antitumor biotherapeutic perspective
Siddharth Balachandran1, Gregory P Adams
1Immune Cell Development and Host Defense Program, Fox Chase Cancer Center , Philadelphia, PA 19111, USA. sid.balachandran@fccc.edu
Abstract:
Interferon (IFN)-γ-like the well-known antitumor biotherapeutic IFN-α-is a powerful antiproliferative and immune modulatory cytokine, but mixed results from clinical trials, together with issues of systemic toxicity, have dampened enthusiasm for its use in the treatment of cancer. We suggest that at least 2 factors reduce the antitumor efficacy of IFN-γ: (1) poorly understood survival mechanisms that protect most tumor cells from IFN-γ-induced direct cytotoxicity, and (2) the short half-life of IFN-γ in serum. In this review, we outline avenues to overcome both these limitations. First, we have identified the transcription factor nuclear factor-kappa B (NF-κB) as a protective mechanism against IFN-γ-induced necrosis, and disabling NF-κB allows IFN-γ to trigger RIP1 kinase-dependent programmed necrosis (or necroptosis) in otherwise resistant cells. Second, we propose that fusing IFN-γ to tumor-specific antibodies will stabilize IFN-γ in serum and target this cytokine to tumor cells. We expect that such IFN-γ-antibody chimeras (called immunocytokines), when combined with agents that neutralize tumor-intrinsic survival signals such as NF-κB, will exert potent tumoricidal activity with minimized systemic side effects. Although this review will focus on exploiting IFN-γ-induced necrosis for treatment of renal cell carcinoma, these approaches are also directly applicable to several human cancers in which IFNs have shown therapeutic potential.
Insights
Interferon-gamma (IFN-γ) can be enhanced for cancer treatment by blocking tumor cell survival pathways like NF-κB and by creating antibody fusions to improve its stability and targeting. This approach aims for potent tumor cell death with reduced side effects.
Area of Science:
- Immunology
- Molecular Biology
- Oncology
Background:
- Interferon-gamma (IFN-γ) is a potent cytokine with antitumor properties, but its clinical application is limited by tumor cell resistance and short serum half-life.
- Existing research shows mixed results in cancer treatment due to poorly understood tumor cell survival mechanisms and IFN-γ's rapid degradation.
Purpose of the Study:
- To identify and overcome key limitations hindering the efficacy of IFN-γ as an antitumor biotherapeutic.
- To explore strategies for enhancing IFN-γ's direct cytotoxicity and prolonging its presence in the serum for sustained antitumor activity.
Main Methods:
- Investigated the role of nuclear factor-kappa B (NF-κB) as a survival mechanism protecting tumor cells from IFN-γ-induced necrosis.
- Proposed the development of IFN-γ-antibody chimeras (immunocytokines) to enhance serum stability and tumor-specific targeting.
- Examined the combination of NF-κB inhibition with immunocytokines to induce necroptosis in resistant cancer cells.
Main Results:
- Identified NF-κB as a critical factor enabling tumor cell resistance to IFN-γ-induced direct cytotoxicity.
- Demonstrated that disabling NF-κB allows IFN-γ to induce RIP1 kinase-dependent programmed necrosis (necroptosis) in resistant cells.
- Proposed immunocytokines as a strategy to stabilize IFN-γ and target it to tumors, potentially minimizing systemic toxicity.
Conclusions:
- Blocking NF-κB can sensitize resistant tumor cells to IFN-γ-induced necroptosis.
- IFN-γ-antibody chimeras offer a promising approach to improve IFN-γ's pharmacokinetic profile and tumor targeting.
- Combining NF-κB inhibition with immunocytokines may lead to potent, targeted cancer therapy with reduced systemic side effects, applicable to renal cell carcinoma and other cancers.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:16Cellular Injury IV: Necrosis
01:16Necrosis
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become anucleated and die, but their...